Copyright medicaldialogues
New Delhi: Wockhardt Ltd has reported a strong turnaround in its quarterly performance, posting a consolidated profit after tax of Rs 82 crore for the second quarter ended September 30, 2025, compared to a loss of Rs 16 crore in the same period last year.However, the company’s revenue from operations declined to Rs 782 crore, compared with Rs 818 crore in the year-ago quarter, Wockhardt said in a statement.The company’s India business contributed Rs 172 crore during the quarter, reflecting a 3 per cent growth compared to the previous year, it added. The UK business generated Rs 313 crore, a growth of 4 per cent compared to the previous year, PTI reported.Besides, the Ireland business stood at Rs 59 crore in the second quarter with a growth of 40 per cent compared to the previous year, it added."We see significant scale up and advancing our leadership in the Biotech diabetes segment on the back of new partnerships in the Emerging markets and India, entry into new markets like Russia and Malaysia as we commit to offer affordable Insulin globally,” it said.Read also: Wockhardt seeks USFDA approval for Zidebactam-Cefepime injection to treat Serious GramNegative InfectionsWockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt has USFDA's QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 79% of its global revenues coming from international businesses.Read also: CDSCO Panel Asks Wockhardt to Revise Phase III Study Protocol for Nafithromycin, Seeks Dosing, Control Arm Changes
